Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
gptkb:physicist
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2017
gptkb:FDA |
| gptkbp:brand |
Ozempic
Wegovy |
| gptkbp:clinical_trial |
Phase 3
diabetes management obesity treatment |
| gptkbp:contraindication |
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
gptkb:medullary_thyroid_carcinoma |
| gptkbp:developed_by |
gptkb:Novo_Nordisk
|
| gptkbp:dosage_form |
injection
0.25 mg weekly 0.5 mg weekly 1 mg weekly 2 mg weekly |
| gptkbp:duration |
long-term
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
semaglutide
|
| gptkbp:indication |
chronic weight management
|
| gptkbp:ingredients |
gptkb:semaglutide
C187 H265 N43 O51 S |
| gptkbp:is_used_for |
weight management
type 2 diabetes |
| gptkbp:lifespan |
about 1 week
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
Ozempic for diabetes
Wegovy for weight loss |
| gptkbp:pharmacokinetics |
subcutaneous absorption
protein binding increases insulin secretion metabolism in liver decreases glucagon secretion slows gastric emptying |
| gptkbp:population |
adults
|
| gptkbp:research_areas |
endocrinology
metabolic syndrome cardiovascular health diabetes treatment obesity treatment |
| gptkbp:side_effect |
nausea
weight loss abdominal pain vomiting diarrhea constipation glycemic control improved cardiovascular outcomes reduction in Hb A1c |
| gptkbp:storage |
refrigerated
|
| gptkbp:weight |
4113.5 g/mol
|
| gptkbp:bfsParent |
gptkb:GLP-1_receptor
|
| gptkbp:bfsLayer |
5
|